Please assess the completion status of the following clinical trial:

Trial Title: Transdermal Insulin Response In Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject has a serum protein HbA1c of less than 6.~2. The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.~3. The subject has a body mass index (BMI) within 18-50 kg/m2.~4. The subject is in otherwise good health as determined by medical history and physical examination.~5. The subject is a non-smoker.~6. The subject must agree to continue with daily serum glucose testing by means of a wearable blood glucose for the pharmacokinetic assessments.~7. The subject is willing and able to comply with all testing and requirements defined in the protocol.~8. The subject is willing and able to return to the study site for all visits.~Exclusion Criteria:~1. The subject has any relevant deviations from normal other than blood glucose in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.~2. The subject has had a clinically significant illness within 30 days preceding entry into this study.~3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.~4. The subject has a known allergy or history of hypersensitivity to Human Insulin or similar modified Insulin compounds.~5. The subject has used any prescription medication that may interfere with the evaluation of study medication.~6. The subject has donated or lost a significant volume of blood (\>450 mL) within four (4) weeks of the study, and their Haemoglobin concentration and haematocrit have not returned to within 5% of normal.~7. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.~8. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).~9. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Main Experimental (Type: EXPERIMENTAL): Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight

Based on this trial design, predict the completion outcome and termination type (if applicable).